Advertisement

Nontuberculous Mycobacterial Disease in Transplant Recipients

  • Julie V. PhilleyEmail author
  • Amar Safdar
  • Charles L. Daley
Chapter

Abstract

The spectrum of nontuberculous mycobacterial (NTM) infections has become an increasingly recognized cause of clinical concern in transplant recipients. While episodic isolation of NTM is often common among certain solid organ transplants such as lung recipients, there is sufficient evidence to support that serious infections can result in all transplant groups. As NTM are ubiquitous in the environment, and exposure to such bacteria is universally unavoidable, clinicians providing care for transplant populations must be up to date regarding the diagnosis and management of infections caused by NTM and maintain a high index of suspicion as clinical signs and symptoms may be insidious.

Keywords

Rapidly Growing Mycobacteria Slowly Growing Mycobacteria Mycobacterium avium intracellulare Nontuberculous Mycobacteria 

References

  1. 1.
    Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax. 2006;61:507–13.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Huang HC, Weigt SS, Derhovanessian A, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant. 2011;30:790–8.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest. 1999;115:741–5.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis. 2012;14:452–60.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Daley CL. Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant. 2009;14:619–24.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36:13–34.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970–6.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax. 2007;62:661–6.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013;19:1889–91.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Yoo JW, Jo KW, Kim SH, et al. Incidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients. Transpl Int. 2016;29:549–58.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Jie T, Matas AJ, Gillingham KJ, Sutherland DE, Dunn DL, Humar A. Mycobacterial infections after kidney transplant. Transplant Proc. 2005;37:937–9.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med. 1999;160:1611–6.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004;38:1428–39.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Longworth SA, Vinnard C, Lee I, Sims KD, Barton TD, Blumberg EA. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transpl Infect Dis. 2014;16:76–83.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Novick RJ, Moreno-Cabral CE, Stinson EB, et al. Nontuberculous mycobacterial infections in heart transplant recipients: a seventeen-year experience. J Heart Transplant. 1990;9:357–63.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Munoz RM, Pulpon LA, Yebra M, Segovia J, San Martin M, Salas C. Three cases of tuberculosis after heart transplantation in Spain. Eur J Clin Microbiol Infect Dis. 1998;17:801–6.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Hall CM, Willcox PA, Swanepoel CR, Kahn D, Van Zyl Smit R. Mycobacterial infection in renal transplant recipients. Chest. 1994;106:435–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Lloveras J, Peterson PK, Simmons RL, Najarian JS. Mycobacterial infections in renal transplant recipients. Seven cases and a review of the literature. Arch Intern Med. 1982;142:888–92.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Delaney V, Sumrani N, Hong JH, Sommer B. Mycobacterial infections in renal allograft recipients. Transplant Proc. 1993;25:2288–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Costa JM, Meyers AM, Botha JR, Conlan AA, Myburgh A. Mycobacterial infections in recipients of kidney allografts. A seventeen-year experience. Acta Medica Port. 1988;1:51–7.Google Scholar
  22. 22.
    Higgins RM, Cahn AP, Porter D, et al. Mycobacterial infections after renal transplantation. Q J Med. 1991;78:145–53.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Vandermarliere A, Van Audenhove A, Peetermans WE, Vanrenterghem Y, Maes B. Mycobacterial infection after renal transplantation in a Western population. Transpl Infect Dis. 2003;5:9–15.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Spence RK, Dafoe DC, Rabin G, et al. Mycobacterial infections in renal allograft recipients. Arch Surg. 1983;118:356–9.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis. 1994;19:263–73.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    George IA, Santos CA, Olsen MA, Bailey TC. Epidemiology and outcomes of nontuberculous mycobacterial infections in solid organ transplant recipients at a Midwestern Center. Transplantation. 2016;100:1073–8.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Shah SK, McAnally KJ, Seoane L, et al. Analysis of pulmonary non-tuberculous mycobacterial infections after lung transplantation. Transpl Infect Dis. 2016;18:585–91.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant. 2006;25:1447–55.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Qvist T, Gilljam M, Jonsson B, et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros. 2015;14:46–52.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Aguilar-Guisado M, Givalda J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant. 2007;7:1989–96.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant. 2007;26:890–7.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Lobo LJ, Chang LC, Esther CR Jr, Gilligan PH, Tulu Z, Noone PG. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transpl. 2013;27:523–9.CrossRefGoogle Scholar
  33. 33.
    Piersimoni C. Nontuberculous mycobacteria infection in solid organ transplant recipients. Eur J Clin Microbiol Infect Dis. 2012;31:397–403.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Queipo JA, Broseta E, Santos M, Sanchez-Plumed J, Budia A, Jimenez-Cruz F. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect. 2003;9:518–25.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Munoz RM, Alonso-Pulpon L, Yebra M, Segovia J, Gallego JC, Daza RM. Intestinal involvement by nontuberculous mycobacteria after heart transplantation. Clin Infect Dis. 2000;30:603–5.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Au WY, Cheng VC, Ho PL, et al. Nontuberculous mycobacterial infections in Chinese hematopoietic stem cell transplantation recipients. Bone Marrow Transplant. 2003;32:709–14.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Gaviria JM, Garcia PJ, Garrido SM, Corey L, Boeckh M. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant. 2000;6:361–9.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant. 1997;19:467–70.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation. 1983;36:509–13.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Weinstock DM, Feinstein MB, Sepkowitz KA, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:1015–21.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Kurzrock R, Zander A, Vellekoop L, Kanojia M, Luna M, Dicke K. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med. 1984;77:35–40.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Beswick J, Shin E, Michelis F, et al. Incidence and risk factors for nontuberculous mycobacterial infection after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(2):366–72. pii: S1083–8791(17)30748–6.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15:968–80.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Rook GA. Macrophages and Mycobacterium tuberculosis: the key to pathogenesis. Immunol Ser. 1994;60:249–61.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity. 2012;36:515–28.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev. 2005;203:38–47.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Liles WC. Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect. 2001;16:11–7.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Deretic V, Singh S, Master S, et al. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism. Cell Microbiol. 2006;8:719–27.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Karim AF, Reba SM, Li Q, Boom WH, Rojas RE. Toll like Receptor 2 engagement on CD4+ T cells promotes TH9 differentiation and function. Eur J Immunol. 2017;47:1513–24.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Su X, Yu Y, Zhong Y, et al. Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat Immunol. 2015;16:838–49.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Ostuni R, Piccolo V, Barozzi I, et al. Latent enhancers activated by stimulation in differentiated cells. Cell. 2013;152:157–71.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Jung JY, Robinson CM. IL-12 and IL-27 regulate the phagolysosomal pathway in mycobacteria-infected human macrophages. Cell Commun Signal. 2014;12:16.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Safdar A, Armstrong D, Murray HW. A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med. 2003;138:521.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Safdar A, White DA, Stover D, Armstrong D, Murray HW. Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med. 2002;113:756–9.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Silva RA, Florido M, Appelberg R. Interleukin-12 primes CD4+ T cells for interferon-gamma production and protective immunity during Mycobacterium avium infection. Immunology. 2001;103:368–74.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Bhattacharyya A, Pathak S, Kundu M, Basu J. Mitogen-activated protein kinases regulate Mycobacterium avium-induced tumor necrosis factor-alpha release from macrophages. FEMS Immunol Med Microbiol. 2002;34:73–80.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Petursdottir DH, Chuquimia OD, Freidl R, Fernandez C. Macrophage control of phagocytosed mycobacteria is increased by factors secreted by alveolar epithelial cells through nitric oxide independent mechanisms. PLoS One. 2014;9:e103411.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–29.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev. 2014;27:727–52.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Ahn CH, Lowell JR, Ahn SS, Ahn S, Hurst GA. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis. 1981;3:1028–34.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis. 1983;128:1048–50.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis. 1981;3:1035–9.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367–76.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Cho YJ, Yi H, Chun J, et al. The genome sequence of 'Mycobacterium massiliense' strain CIP 108297 suggests the independent taxonomic status of the Mycobacterium abscessus complex at the subspecies level. PLoS One. 2013;8:e81560.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Tortoli E, Kohl TA, Brown-Elliott BA, et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol. 2016;66:4471–9.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Harada T, Akiyama Y, Kurashima A, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012;50:3556–61.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183:405–10.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Lyu J, Jang HJ, Song JW, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med. 2011;105:781–7.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Knoll BM. Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients. Curr Infect Dis Rep. 2014;16:421.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med. 1993;119:482–6.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Heironimus JD, Winn RE, Collins CB. Cutaneous nonpulmonary Mycobacterium chelonei infection. Successful treatment with sulfonamides in an immunosuppressed patient. Arch Dermatol. 1984;120:1061–3.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Fan MH, Hadjiliadis D. Incidence and management of mycobacterial infection in solid organ transplant recipients. Curr Infect Dis Rep. 2009;11:216–22.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM, Hosts ESGoIiC. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):89–101.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Abad CLRR. Non-tuberculous mycobacterial infections in solid organ transplant recipients: an update. J Clin Tuberc Other Mycobact Dis. 2016;4:1–8.CrossRefGoogle Scholar
  76. 76.
    Fairhurst RM, Kubak BM, Shpiner RB, Levine MS, Pegues DA, Ardehali A. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant. 2002;21:391–4.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Keating MR, Daly JS, Practice ASTIDCo. Nontuberculous mycobacterial infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):77–82.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Dorman S, Subramanian A, Practice ASTIDCo. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S63–9.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Pandian TK, Deziel PJ, Otley CC, Eid AJ, Razonable RR. Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis. 2008;10:358–63.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Jacobson K, Garcia R, Libshitz H, et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis. 1998;17:615–21.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis. 1992;166:405–12.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Shields RK, Clancy CJ, Minces LR, et al. Epidemiology and outcomes of deep surgical site infections following lung transplantation. Am J Transplant. 2013;13:2137–45.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Safdar A, Bains M, Polsky B. Clinical microbiological case: refractory chest wall infection following reconstructive surgery in a patient with relapsed lung cancer. Clin Microbiol Infect. 2001;7:563–4. 77–9.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Engler HD, Hass A, Hodes DS, Bottone EJ. Mycobacterium chelonei infection of a Broviac catheter insertion site. Eur J Clin Microbiol Infect Dis. 1989;8:521–3.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Skiest DJ, Levi ME. Catheter-related bacteremia due to Mycobacterium smegmatis. South Med J. 1998;91:36–7.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Woo PC, Tsoi HW, Leung KW, et al. Identification of Mycobacterium neoaurum isolated from a neutropenic patient with catheter-related bacteremia by 16S rRNA sequencing. J Clin Microbiol. 2000;38:3515–7.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Koranyi KI, Ranalli MA. Mycobacterium aurum bacteremia in an immunocompromised child. Pediatr Infect Dis J. 2003;22:1108–9.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Kiska DL, Turenne CY, Dubansky AS, Domachowske JB. First case report of catheter-related bacteremia due to “Mycobacterium lacticola”. J Clin Microbiol. 2004;42:2855–7.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Lee SA, Raad II, Adachi JA, Han XY. Catheter-related bloodstream infection caused by Mycobacterium brumae. J Clin Microbiol. 2004;42:5429–31.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Ashford DA, Kellerman S, Yakrus M, et al. Pseudo-outbreak of septicemia due to rapidly growing mycobacteria associated with extrinsic contamination of culture supplement. J Clin Microbiol. 1997;35:2040–2.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Fraser VJ, Jones M, Murray PR, Medoff G, Zhang Y, Wallace RJ Jr. Contamination of flexible fiberoptic bronchoscopes with Mycobacterium chelonae linked to an automated bronchoscope disinfection machine. Am Rev Respir Dis. 1992;145:853–5.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Longworth SA, Blumberg EA, Barton TD, Vinnard C. Non-tuberculous mycobacterial infections after solid organ transplantation: a survival analysis. Clin Microbiol Infect. 2015;21:43–7.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Al-Anazi KA, Al-Jasser AM, Al-Anazi WK. Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation. Front Oncol. 2014;4:311.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195:814–23.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med. 2015;36:43–54.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Meier A, Heifets L, Wallace RJ Jr, et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis. 1996;174:354–60.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928–34.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Griffith DE. Management of disease due to Mycobacterium kansasii. Clin Chest Med. 2002;23:613–21. viPubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003;37:1178–82.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest. 2006;129:771–6.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    White MH, Papadopoulos EB, Small TN, Kiehn TE, Armstrong D. Mycobacterium haemophilum infections in bone marrow transplant recipients. Transplantation. 1995;60:957–60.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Baluch A, Pasikhova Y, Snyder M. Successful management of Mycobacterium haemophilum lower extremity cutaneous infection in a matched-unrelated donor stem cell transplant recipient. Transpl Infect Dis. 2017;19(1):e12627.  https://doi.org/10.1111/tid.12627.CrossRefGoogle Scholar
  103. 103.
    Gombert ME, Goldstein EJ, Corrado ML, Stein AJ, Butt KM. Disseminated Mycobacterium marinum infection after renal transplantation. Ann Intern Med. 1981;94:486–7.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Jacobs S, George A, Papanicolaou GA, et al. Disseminated Mycobacterium marinum infection in a hematopoietic stem cell transplant recipient. Transpl Infect Dis. 2012;14:410–4.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180:896–902.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52:565–71.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ 3rd. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother. 1992;36:180–4.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Hadjiliadis D, Adlakha A, Prakash UB. Rapidly growing mycobacterial lung infection in association with esophageal disorders. Mayo Clin Proc. 1999;74:45–51.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. Fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1991;35:773–5.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997;63:1278–86.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985–92.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including Clofazimine and/or Rifampin. Chest. 2016;149:1285–93.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of Clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017;152(4):800–9.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Yang B, Jhun BW, Moon SM, et al. Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2017;61(6):e02052–16.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Cariello PF, Kwak EJ, Abdel-Massih RC, Silveira FP. Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients. Transpl Infect Dis. 2015;17:111–8.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Parizhskaya M, Youssef NN, Di Lorenzo C, Goyal RK. Clofazimine enteropathy in a pediatric bone marrow transplant recipient. J Pediatr. 2001;138:574–6.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the pulmonary transplantation Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2015;34:1–15.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax. 2016;71:88–90.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Qvist T, Pressler T, Thomsen VO, Skov M, Iversen M, Katzenstein TL. Nontuberculous mycobacterial disease is not a contraindication to lung transplantation in patients with cystic fibrosis: a retrospective analysis in a Danish patient population. Transplant Proc. 2013;45:342–5.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Sax H, Bloemberg G, Hasse B, et al. Prolonged outbreak of Mycobacterium chimaera infection after open-chest heart surgery. Clin Infect Dis. 2015;61:67–75.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Baker AW, Lewis SS, Alexander BD, et al. Two-phase hospital-associated outbreak of Mycobacterium abscessus: investigation and mitigation. Clin Infect Dis. 2017;64:902–11.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012;185:231–2.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381:1551–60.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016;354:751–7.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Saiman L, Siegel J. Cystic Fibrosis Foundation Consensus Conference on Infection Control P. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control. 2003;31:S1–62.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335:392–8.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;335:384–91.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Julie V. Philley
    • 1
    Email author
  • Amar Safdar
    • 2
  • Charles L. Daley
    • 3
  1. 1.University of Texas Health Science Center at Tyler, Department of Pulmonary and Critical Care MedicineTylerUSA
  2. 2.Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of MedicineEl PasoUSA
  3. 3.Division of Mycobacterial and Respiratory InfectionsNational Jewish Health and University of ColoradoDenverUSA

Personalised recommendations